Form 4: Emergent BioSolutions Director Receives Stock Grant and Options

John D. Fowler Jr., a Director at Emergent BioSolutions Inc., was granted restricted stock units and stock options on April 30, 2026, as part of his compensation for board service.

Summary

• Director John D. Fowler Jr. received an annual grant of 25,344 restricted stock units (RSUs) on April 30, 2026.
• These RSUs represent a right to receive one share of Emergent BioSolutions Inc. common stock upon vesting.
• The RSUs are subject to vesting on the day prior to the one-year anniversary of the grant date, provided Mr. Fowler remains a director.
• Additionally, Mr. Fowler was granted 11,296 stock options with an exercise price of $7.99.
• These stock options also vest on the one-year anniversary of the grant date, contingent on continued board membership.
• The number of options granted was calculated based on 25% of the total non-employee director compensation value and the Black-Scholes value of a single option.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it pertains to standard director compensation and does not provide insights into the company's financial performance or strategic direction.

Positives

• Director compensation includes equity awards (RSUs and stock options), aligning director interests with shareholders.
• The grant of RSUs and options indicates continued confidence in the company's long-term prospects by its directors.
• The equity awards are structured to incentivize continued service and performance through vesting requirements.

Negatives

• The filing does not provide information on the company's financial performance or operational status, focusing solely on insider transactions.
• The exercise price of the stock options ($7.99) may be above the current market price, depending on the stock's trading performance.

Risks

• Vesting of RSUs and stock options is contingent on the reporting person remaining a member of the Company's board of directors, implying a risk of forfeiture if the director resigns or is removed.
• The value of the equity awards is subject to market fluctuations and the company's future stock performance.

Future Outlook

The future outlook is not directly addressed in this filing, which focuses on equity grants to a director. The vesting conditions for the RSUs and stock options imply a forward-looking expectation of continued board service and company performance.

Management Comments

• The filing details compensation arrangements for board service, indicating a structured approach to director remuneration.
• The explanations clarify the nature of the RSUs and stock options, including their vesting schedules and the basis for option grant calculations.

Industry Context

StockSavvy.ai notes that the issuance of equity awards to directors is a common practice across the biotechnology and pharmaceutical industries to attract and retain experienced leadership and align their interests with shareholders.

Corporate Governance

Related Party Transactions

• The grant of equity awards to Director John D. Fowler Jr. constitutes a related party transaction, as it is compensation for his services as a director.

Stakeholder Impact

• Shareholders: The equity grants are a form of compensation that dilutes existing share ownership upon vesting and exercise, but also aims to align director interests with shareholder value creation.
• Employees: This filing does not directly impact employees, but reflects the company's compensation philosophy for its board.
• Management: The compensation structure for directors is set by the board, often with input from management and compensation committees.

Next Steps

• Mr. Fowler must remain a director through the Annual Grant Vesting Date (one year from grant date) for the RSUs and stock options to vest.
• The stock options can be exercised after vesting until their expiration date in 2033.

Key Dates

Keywords

Form 4, Insider Transaction, Emergent BioSolutions, EBS, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership